We’re helping to turn research dreams into reality.

The DREAM Award (Dataset Research Engagement and ATHN Mentorship Award) is the first mentored research award offered through the collaboration of Hemostasis and Thrombosis Research Society (HTRS) and ATHN. Designed to enhance the care of patients with bleeding and clotting disorders, the award provides up to $100,000 over 24 months for young investigators at ATHN-affiliated U.S. hemophilia treatments centers (HTCs), working under the guidance of experienced mentors.

DREAM Award recipients recognize that the ATHNdataset provides a powerful database that can be used as a starting point to answer a research question or design and test a quality metric. Creative approaches addressing issues of significance are the hallmark of award-winning proposals.

  • Studies using the national ATHNdataset may advance the care of the entire population or a subset of patients with hemophilia, von Willebrand disease, rare bleeding disorders, platelet disorders or thrombotic disorders
  • Projects can use data from the existing ATHNdataset exclusively or augment it by adding complementary data to be collected in local or regional multi-center collaborations
  • Methodology may feature longitudinal, case/control, feasibility, comparative effectiveness or cost effectiveness approaches
  • Researchers may be fellows and early stage investigators dedicated to a career in benign hematology.

2015 DREAM Award Recipients

Congratulations to the following DREAM Awardees:

[photo]

Project Title: Regional and center-level variation in utilization of orthopedic surgical interventions in persons with hemophilia
Abstract: This study evaluates predictors of and outcomes associated with orthopedic surgical procedures in individuals with hemophilia. The study's results will help to guide future efforts to improve perioperative and long-term outcomes associated with these procedures. The aims of this study are to determine whether regional differences or HTC size affect the utilization of invasive joint surgeries and to quantify the impact of orthopedic surgery on the frequency of opioid use in men with hemophilia. Evaluation of additional outcomes that may be affected by surgery will allow us to identify other potential measures of treatment effectiveness and care quality.
Mentor: Marilyn Manco-Johnson, MD, Professor of Pediatrics, Director of University of Colorado HTC

[photo]

Project Title: Inhibitors in non-severe hemophilia A patients
Abstract: Using the ATHNdataset as a source population consisting of 3,821 (44.7%) non-severe hemophilia A (NSHA) patients (per ATHN Research Brief Report, March 31, 2015), this retrospective cohort study seeks to determine the mortality rate, cumulative inhibitor incidence, clinical presentation, and therapeutic approaches for inhibitor eradication (if any), and their resultant outcome of NSHA patients with inhibitors throughout the United States over a 35 year period (January 1, 1981 to December 31, 2015).
Mentor: Nigel Key, MB, ChB, FRCP, Director, University of North Carolina Hemophilia and Thrombosis Center

The 2015 DREAM Award was made possible through an educational grant from Baxalta.

2016 DREAM Award Recipients

Congratulations to the following DREAM Awardees:

[photo]

Project Title: Is Prophylaxis Putting Hemophilia Joints in the PINK: An ATHN-LINKED Observational Study
Abstract: The overall objective of this study is to discern use the impact of extended half-life (EHL) products in prophylaxis by determining the proportion of patients with severe hemophilia adopting its use and the impact on bleeding events, joint health and quality of life. 
Mentor: Margaret V. Ragni, MD, Professor of Medicine, University of Pittsburgh

[photo]

Project Title: Evolving Real-World Use of Standard and EHL Products in Moderate and Severe Hemophilia Patients: A Practical Application of the ATHNdataset
Abstract: This longitudinal, observational study characterizes the evolving real-world use of factor replacement products for patients with moderate and severe hemophilia A and B without inhibitors. Serial queries of the ATHNdataset at eight-month intervals will compare the proportions of factor products prescribed, median weekly factor consumption and annual infusion rate by factor product and the impact of EHL products on prophylaxis rates. In order to test the quality (timeliness and accuracy) of ATHNdataset and the feasibility of using it as a PK data repository, a 10-site real-time data entry pilot will be conducted as a sub-study.
Mentor: Ellis J. Neufeld, MD, PhD, Professor of Pediatrics, Boston Children's Hospital

[photo]

Project Title: Characteristics Associated with Prescribed Prophylaxis of Factor Replacement
Abstract: Prophylactic factor replacement therapy is recommended for patients with severe hemophilia A and B to reduce joint disease. The characteristics of those with prescribed prophylaxis are not well described. This cross-sectional design study proposes to describe the characteristics of patients with severe hemophilia that are prescribed prophylaxis using CORE data elements of the ATHNdataset. Additionally, an exploratory aim would research neighborhood variables to identify potential social/environmental determinants of prescribed prophylaxis through geographic information systems.
Mentor: Christine Kempton, MD, MSc, Associate Professor, Department of Pediatrics and Hemophilia/Medical Oncology, Hemophilia of Georgia

The 2016 DREAM Award was funded through the generosity of Hemophilia of Georgia.

The DREAM Award

Deadline for Submission

Estimated Start Date

2015-2016

Pre-proposal: June 1, 2015
Proposal: October 5, 2015

July 1, 2016

2017

Pre-proposal: June 1, 2016
Proposal: August 29, 2016

July 1, 2017